Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis
Status:
Unknown status
Trial end date:
2019-12-11
Target enrollment:
Participant gender:
Summary
This is a phase Ib study to investigate the safety, pharmacokinetics and preliminary efficacy
of ginsenoside compound K (GCK) tablets in patients with rheumatoid arthritis. This study is
to be run in China involving 10-12 sites. It will enroll approximately 240 patients to ensure
128 randomized with active rheumatoid arthritis. The treatment period is 12 weeks and total
study duration per patient is approximately 14 weeks.